Clomipramine and imipramine in obsessive-compulsive disorder

Area of Science:

• Psychiatry and Behavioral Sciences
• Clinical Pharmacology

Background:

• Obsessive-compulsive disorder (OCD) is a debilitating mental health condition.
• Pharmacological treatments, including tricyclic antidepressants, are a cornerstone of OCD management.
• Comparative efficacy of different agents requires ongoing investigation.

Purpose of the Study:

• To compare the efficacy and safety of clomipramine (CLI) versus imipramine (IMI) in treating primary OCD.
• To assess the impact of these treatments on both OCD symptoms and comorbid depressive symptoms.

Main Methods:

• A 12-week, double-blind, randomized clinical trial involving 23 outpatients with primary OCD.
• Participants were assigned to either clomipramine (n=11) or imipramine (n=12) without placebo or crossover.
• Symptom severity was assessed at baseline, week 6, and week 12.

Main Results:

• Both clomipramine and imipramine demonstrated modest reductions in OCD symptoms from baseline.
• Both agents exhibited significant antidepressant effects.
• Clomipramine showed a marginally superior effect on both OCD and depressive symptoms compared to imipramine, even after adjusting for baseline severity.

Conclusions:

• Clomipramine and imipramine are effective in treating OCD and associated depression.
• Clomipramine may offer a slightly greater therapeutic benefit for OCD and depression compared to imipramine.
• The observed effects on OCD were independent of baseline depression severity, and no significant safety differences were noted between the two drugs.